Immunosuppressive drugs such as corticosteroids and methotrexate, cytokine targeting agents, JAK2 inhibitors, and the hypomethylating agent azacytidine are some of the therapeutic agents used to treat VEXAS syndrome.[16,17] JAK inhibitors are increasingly used in the treatment of inflammatory and autoimmune diseases and appear to be promising agents because they inhibit cytokines, which drive inflammation and prevent myelofibrosis.[18,19] More data regarding treatment effectiveness are needed to improve the quality of life and outcomes of patients with VEXAS. This evidence concerns the gene JAK2 and autoimmune disease.